Clinical Trials Directory

Trials / Conditions / Stage III Renal Cell Cancer AJCC v7

Stage III Renal Cell Cancer AJCC v7

13 registered clinical trials studyying Stage III Renal Cell Cancer AJCC v7.

StatusTrialSponsorPhase
Active Not RecruitingNivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy
NCT03055013
National Cancer Institute (NCI)Phase 3
CompletedSitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer
NCT03015740
M.D. Anderson Cancer CenterPhase 1 / Phase 2
CompletedTesting Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed
NCT02761057
National Cancer Institute (NCI)Phase 2
TerminatedNivolumab in Treating Patients With High-Risk Kidney Cancer Before Surgery
NCT02595918
National Cancer Institute (NCI)Phase 1
CompletedCabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or M
NCT01835158
National Cancer Institute (NCI)Phase 2
CompletedRomidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfun
NCT01638533
National Cancer Institute (NCI)Phase 1
CompletedTrebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Tr
NCT01664182
National Cancer Institute (NCI)Phase 2
Active Not RecruitingAkt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostat
NCT01480154
National Cancer Institute (NCI)Phase 1
TerminatedAkt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer
NCT01239342
National Cancer Institute (NCI)Phase 2
TerminatedEverolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After
NCT01198158
National Cancer Institute (NCI)Phase 3
Active Not RecruitingEntinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer
NCT01038778
National Cancer Institute (NCI)Phase 1 / Phase 2
CompletedSunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
NCT00326898
National Cancer Institute (NCI)Phase 3
CompletedSorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cance
NCT00121251
National Cancer Institute (NCI)Phase 1 / Phase 2